Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Afatinib + bevacizumab combination therapy in EGFR-mutant NSCLC patients with osimertinib resistance: Protocol of an open-label, phase II, multicenter, single-arm trial.
Kobayashi N, Hashimoto H, Kamimaki C, Nagasawa R, Tanaka K, Kubo S, Katakura S, Chen H, Hirama N, Ushio R, Aoki A, Nakashima K, Teranishi S, Manabe S, Watanabe H, Horita N, Watanabe K, Hara Y, Yamamoto M, Kudo M, Piao H, Kaneko T. Kobayashi N, et al. Among authors: teranishi s. Thorac Cancer. 2020 Aug;11(8):2125-2129. doi: 10.1111/1759-7714.13503. Epub 2020 Jun 3. Thorac Cancer. 2020. PMID: 32495514 Free PMC article. Clinical Trial.
MicroRNA-200b is a potential biomarker of the expression of PD-L1 in patients with lung cancer.
Katakura S, Kobayashi N, Hashimoto H, Kamimaki C, Tanaka K, Kubo S, Nakashima K, Teranishi S, Manabe S, Watanabe K, Horita N, Hara Y, Yamamoto M, Kudo M, Piao H, Kaneko T. Katakura S, et al. Among authors: teranishi s. Thorac Cancer. 2020 Oct;11(10):2975-2982. doi: 10.1111/1759-7714.13653. Epub 2020 Sep 7. Thorac Cancer. 2020. PMID: 32893980 Free PMC article.
Identification of a novel biomarker based on lymphocyte count, albumin level, and TBAg/PHA ratio for differentiation between active and latent tuberculosis infection in Japan.
Katakura S, Kobayashi N, Hashimoto H, Kamimaki C, Tanaka K, Kubo S, Nakashima K, Teranishi S, Watanabe K, Hara Y, Yamamoto M, Kudo M, Piao H, Kaneko T. Katakura S, et al. Among authors: teranishi s. Tuberculosis (Edinb). 2020 Dec;125:101992. doi: 10.1016/j.tube.2020.101992. Epub 2020 Sep 11. Tuberculosis (Edinb). 2020. PMID: 32957053
T-cell response to phytohemagglutinin in the interferon-γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non-small cell lung cancer.
Kamimaki C, Kobayashi N, Hirata M, Somekawa K, Fukuda N, Kubo S, Katakura S, Teranishi S, Watanabe K, Horita N, Hara Y, Yamamoto M, Kudo M, Piao H, Kaneko T. Kamimaki C, et al. Among authors: teranishi s. Thorac Cancer. 2021 Jun;12(11):1726-1734. doi: 10.1111/1759-7714.13978. Epub 2021 May 4. Thorac Cancer. 2021. PMID: 33943031 Free PMC article.
Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.
Ushio R, Yamamoto M, Miyasaka A, Muraoka T, Kanaoka H, Tamura H, Kaneko A, Izawa A, Hirama N, Teranishi S, Manabe S, Inoue T, Shibata K, Sugiura Y, Kudo M, Kaneko T. Ushio R, et al. Among authors: teranishi s. Intern Med. 2021 Nov 15;60(22):3593-3598. doi: 10.2169/internalmedicine.6410-20. Epub 2021 Jun 5. Intern Med. 2021. PMID: 34092725 Free PMC article.
Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial.
Matsumoto H, Kobayashi N, Somekawa K, Fukuda N, Kaneko A, Kamimaki C, Kubo S, Tanaka K, Tagami Y, Teranishi S, Watanabe K, Horita N, Hara Y, Yamamoto M, Kudo M, Koizumi H, Miura K, Miyazawa N, Kaneko T. Matsumoto H, et al. Among authors: teranishi s. Thorac Cancer. 2022 Jan;13(2):228-235. doi: 10.1111/1759-7714.14252. Epub 2021 Dec 5. Thorac Cancer. 2022. PMID: 34866339 Free PMC article.
89 results